Autolus Therapeutics (AUTL) Receivables (2021 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Receivables data on file, last reported at $24.9 million in Q4 2025.

• Quarterly Receivables rose 4828.66% year-over-year to $24.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.9 million (up 4828.66% YoY) and the FY2025 annual result came in at $24.9 million, up 1636.7% from the prior year.
• Receivables eased to $24.9 million in Q4 2025, from $33.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $33.5 million in Q3 2025 to a low of $506000.0 in Q4 2024.
• A 5-year average of $6.5 million and a median of $1.7 million in 2022 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables sank 78.44% — and 2025, when it surged 5508.7%.
• Tracing AUTL's Receivables over 5 years: stood at $655000.0 in 2021, then soared by 137.56% to $1.6 million in 2022, then tumbled by 59.83% to $625000.0 in 2023, then decreased by 19.04% to $506000.0 in 2024, then jumped by 4828.66% to $24.9 million in 2025.
• The last three Receivables figures came in at $24.9 million (Q4 2025), $33.5 million (Q3 2025), and $27.3 million (Q2 2025), per Business Quant data.